Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Bioteknik |
Double Bond Pharmaceutical International AB (publ) ("DBP" or "Company") which is a distributor of Temodex continues to work with its partners to register the product in Latin America and China. Today, DBP has received a purchase order for 3 Temodex vials worth approximately $ 10k from its partner in Columbia.
"There is a great interest in Temodex/SI-053 in different parts of the world and while we are commencing clinical trials phase I with SI-053 in EU, we will commercialize Temodex on other available markets. With the current order we are happy to provide doctors and patients with brain cancer our innovative product" - commented Igor Lokot, CEO of DBP. "Latin America is a large market and can generate a lucrative business for the Company" - Igor Lokot adds.